Upcoming clinical studies to be carried out at Profil
Recently, Adocia has announced two new studies to be carried out. These are a clinical study on a high concentration formulation of the ultrarapid acting insulin BioChaperone Lispro as well as a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes. Both studies will be carried out by Profil, the reliable and trusted partner of Adocia when it comes to early phase clinical trials for their BioChaperone development.
Developing a post-prandial ultra-rapid insulin lispro
In June, at the ADA Scientific Sessions in Boston, Profil presented the results of another recent study sponsored by Adocia and the results will also be discussed at the upcoming EASD-meeting in Stockholm. You can download the poster here. The poster presentation was met with great interest as it showed that ultra-rapid BioChaperone Insulin Lispro has a faster onset of action and a stronger early metabolic effect than conventional insulin lispro. Therefore BioChaperone Insulin Lispro has the potential to achieve a better postprandial glucose control. In addition BioChaperone Lispro, because of its ultra-rapid properties might offer the option of an insulin injection immediatly before or even after starting a meal. Achieving this goal should improve the quality of life of patients with diabetes offering more flexibility in the timing and adjustment of insulin dosings around meals.